{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:49:14Z","timestamp":1791204554017,"version":"4.2.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0224-3","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T12:24:37Z","timestamp":1448022277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":251,"title":["ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development"],"prefix":"10.1186","volume":"8","author":[{"given":"Shundong","family":"Cang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Iragavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Savooji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"issue":"1","key":"224_CR1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-8722-6-90","volume":"6","author":"M Furqan","year":"2013","unstructured":"Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):90.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2050-7771-1-5","volume":"1","author":"M Furqan","year":"2013","unstructured":"Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5.","journal-title":"Biomark Res"},{"issue":"1","key":"224_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-8722-6-30","volume":"6","author":"T Huang","year":"2013","unstructured":"Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):30.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-6-23","volume":"6","author":"M Saha","year":"2013","unstructured":"Saha M, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):23.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"224_CR7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"12","key":"224_CR8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"1","key":"224_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","volume":"6","author":"J Mellor","year":"2013","unstructured":"Mellor J, Brown M, Irving H, Zalcberg J, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6(1):1.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","volume":"7","author":"T Suresh","year":"2014","unstructured":"Suresh T, Lee L, Joshi J, Barta S. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.","journal-title":"J Hematol Oncol"},{"key":"224_CR11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"224_CR12","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"9980","key":"224_CR13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873\u201383.","journal-title":"Lancet"},{"issue":"4","key":"224_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"21","key":"224_CR15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"17","key":"224_CR16","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"issue":"21","key":"224_CR17","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"224_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"26","key":"224_CR19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"224_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","volume":"3","author":"A Novero","year":"2014","unstructured":"Novero A, Ravella P, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3(1):4.","journal-title":"Exp Hematol Oncol"},{"key":"224_CR22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"224_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"224_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"224_CR25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-6-47","volume":"6","author":"E Han","year":"2013","unstructured":"Han E, Li X-l, Wang C-r, Li T-f, Han S-Y. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6(1):47.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"224_CR26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2012","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2012;121(7):1165\u201374.","journal-title":"Blood"},{"issue":"21","key":"224_CR27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood.V124.21.966.966","volume":"124","author":"M Ruella","year":"2014","unstructured":"Ruella M, Barrett D, Kenderian SS, Shestova O, Hofmann TJ, Scholler J, et al. Novel chimeric antigen receptor T cells for the treatment of CD19-negative relapses occurring after CD19-targeted immunotherapies. Blood. 2014;124(21):966.","journal-title":"Blood"},{"key":"224_CR28","first-page":"2","volume":"1","author":"Y Chen","year":"2014","unstructured":"Chen Y, Liu D. Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Investig. 2014;1:2.","journal-title":"Stem Cell Investig"},{"issue":"4","key":"224_CR29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"3","key":"224_CR30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014;6(3):728\u201373.","journal-title":"MAbs"},{"issue":"26","key":"224_CR31","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024\u201331.","journal-title":"Blood"},{"issue":"1","key":"224_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-8722-7-33","volume":"7","author":"C Breton","year":"2014","unstructured":"Breton C, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol. 2014;7(1):33.","journal-title":"J Hematol Oncol"},{"key":"224_CR33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104.","journal-title":"J Hematol Oncol"},{"issue":"4678","key":"224_CR34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097\u20139.","journal-title":"Science"},{"issue":"1","key":"224_CR35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(99)01761-5","volume":"466","author":"Y Tsujimoto","year":"2000","unstructured":"Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett. 2000;466(1):6\u201310.","journal-title":"FEBS Lett"},{"issue":"11","key":"224_CR36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","volume":"3","author":"Y Tsujimoto","year":"1998","unstructured":"Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3(11):697\u2013707.","journal-title":"Genes Cells"},{"issue":"1","key":"224_CR37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/MCB.22.1.94-104.2002","volume":"22","author":"DS McClintock","year":"2002","unstructured":"McClintock DS, Santore MT, Lee VY, Brunelle J, Budinger GR, Zong WX, et al. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol Cell Biol. 2002;22(1):94\u2013104.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"224_CR38","first-page":"1483","volume":"63","author":"H Yamaguchi","year":"2003","unstructured":"Yamaguchi H, Bhalla K, Wang HG. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac\/Diablo and Omi\/HtrA2 release from mitochondria. Cancer Res. 2003;63(7):1483\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"224_CR39","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1084\/jem.184.4.1331","volume":"184","author":"SA Susin","year":"1996","unstructured":"Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 1996;184(4):1331\u201341.","journal-title":"J Exp Med"},{"issue":"5303","key":"224_CR40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","volume":"275","author":"RM Kluck","year":"1997","unstructured":"Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132\u20136.","journal-title":"Science"},{"issue":"5303","key":"224_CR41","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275(5303):1129\u201332.","journal-title":"Science"},{"issue":"5381","key":"224_CR42","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","volume":"281","author":"JM Adams","year":"1998","unstructured":"Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281(5381):1322\u20136.","journal-title":"Science"},{"issue":"8","key":"224_CR43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0962-8924(98)01321-X","volume":"8","author":"A Kelekar","year":"1998","unstructured":"Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998;8(8):324\u201330.","journal-title":"Trends Cell Biol"},{"key":"224_CR44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395\u2013419.","journal-title":"Annu Rev Immunol"},{"issue":"7042","key":"224_CR45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677\u201381.","journal-title":"Nature"},{"issue":"16","key":"224_CR46","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","volume":"26","author":"D Chauhan","year":"2007","unstructured":"Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374\u201380.","journal-title":"Oncogene"},{"issue":"7","key":"224_CR47","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.leu.2404719","volume":"21","author":"MP Kline","year":"2007","unstructured":"Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007;21(7):1549\u201360.","journal-title":"Leukemia"},{"issue":"5","key":"224_CR48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375\u201388.","journal-title":"Cancer Cell"},{"issue":"4","key":"224_CR49","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","volume":"111","author":"MV Gaizo Del","year":"2008","unstructured":"Del Gaizo MV, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111(4):2300\u20139.","journal-title":"Blood"},{"issue":"2","key":"224_CR50","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2011.11.030","volume":"317","author":"K Ishitsuka","year":"2012","unstructured":"Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, et al. Targeting Bcl-2 family proteins in adult T-cell leukemia\/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett. 2012;317(2):218\u201325.","journal-title":"Cancer Lett"},{"issue":"46","key":"224_CR51","doi-asserted-by":"crossref","first-page":"17961","DOI":"10.1073\/pnas.0809957105","volume":"105","author":"KD Mason","year":"2008","unstructured":"Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A. 2008;105(46):17961\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"224_CR52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","volume":"77","author":"LM High","year":"2010","unstructured":"High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O\u2019Brien R, Khaw SL, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010;77(3):483\u201394.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"224_CR53","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","volume":"110","author":"MH Kang","year":"2007","unstructured":"Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 2007;110(6):2057\u201366.","journal-title":"Blood"},{"issue":"6","key":"224_CR54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","volume":"50","author":"R Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(6):1181\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"224_CR55","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7(10):3265\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"224_CR56","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","volume":"20","author":"S Suryani","year":"2014","unstructured":"Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20(17):4520\u201331.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"224_CR57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1476-5381.2012.02048.x","volume":"167","author":"S Ackler","year":"2012","unstructured":"Ackler S, Mitten MJ, Chen J, Clarin J, Foster K, Jin S, et al. Navitoclax (ABT-263) and bendamustine +\/- rituximab induce enhanced killing of non-Hodgkin\u2019s lymphoma tumours in vivo. Br J Pharmacol. 2012;167(4):881\u201391.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"224_CR58","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00280-009-1232-1","volume":"66","author":"S Ackler","year":"2010","unstructured":"Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66(5):869\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"224_CR59","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149\u201359.","journal-title":"Lancet Oncol"},{"issue":"5","key":"224_CR60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488\u201396.","journal-title":"J Clin Oncol"},{"issue":"5","key":"224_CR61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943\u201351.","journal-title":"Cell Death Differ"},{"issue":"6","key":"224_CR62","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173\u201386.","journal-title":"Cell"},{"issue":"2","key":"224_CR63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"224_CR64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12457","volume":"163","author":"M Vogler","year":"2013","unstructured":"Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139\u201342.","journal-title":"Br J Haematol"},{"issue":"3","key":"224_CR65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362\u201375.","journal-title":"Cancer Discov"},{"issue":"6","key":"224_CR66","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","volume":"28","author":"SL Khaw","year":"2014","unstructured":"Khaw SL, Merino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28(6):1207\u201315.","journal-title":"Leukemia"},{"issue":"12","key":"224_CR67","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121(12):2285\u20138.","journal-title":"Blood"},{"issue":"25","key":"224_CR68","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood"},{"key":"224_CR69","doi-asserted-by":"crossref","unstructured":"Bodo J, Zhao X, Smith MR, Hsi ED. Activity of ABT-199 and acquired resistance in follicular lymphoma cells. Blood. 2014;124(21):3635\u20135.","DOI":"10.1182\/blood.V124.21.3635.3635"},{"key":"224_CR70","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober WD, et al. Cooperative targeting of Bcl-2 family proteins by ABT-199 (GDC-0199) and tyrosine kinase inhibitors to eradicate blast crisis CML and CML stem\/progenitor cells. Blood. 2014;124(21):512\u20132.","DOI":"10.1182\/blood.V124.21.512.512"},{"key":"224_CR71","doi-asserted-by":"crossref","unstructured":"Portell CA, Axelrod M, Brett LK, Gordon VL, Capaldo B, Xing JC, et al. Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions. Blood. 2014;124(21):509\u20139.","DOI":"10.1182\/blood.V124.21.509.509"},{"issue":"1","key":"224_CR72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-014-0067-3","volume":"7","author":"J Gerecitano","year":"2014","unstructured":"Gerecitano J. SINE (selective inhibitor of nuclear export) - translational science in a new class of anti-cancer agents. J Hematol Oncol. 2014;7(1):67.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"G Gravina","year":"2014","unstructured":"Gravina G, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7(1):85.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-7-46","volume":"7","author":"G Gravina","year":"2014","unstructured":"Gravina G, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, et al. XPO1\/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol. 2014;7(1):46.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"224_CR75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78.","journal-title":"J Hematol Oncol"},{"key":"224_CR76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","volume":"4","author":"A Das","year":"2015","unstructured":"Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7.","journal-title":"Exp Hematol Oncol"},{"key":"224_CR77","doi-asserted-by":"crossref","unstructured":"Tabe Y, Harada M, Miyamae Y, Kazuno S, Fujimura T, Ueno T, et al. Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of BTK inhibitor ibrutinib in mantle cell lymphoma. Blood. 2014;124(21):2254\u20134.","DOI":"10.1182\/blood.V124.21.2254.2254"},{"issue":"1","key":"224_CR78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S Lu","year":"2014","unstructured":"Lu S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014;7(1):2.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"224_CR79","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","volume":"90","author":"KM Kozopas","year":"1993","unstructured":"Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993;90(8):3516\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"224_CR80","doi-asserted-by":"crossref","unstructured":"Klanova M, Andera L, Soukup J, Jan B, Svadlenka J, Benesova S, et al. MCL1 targeting agent homoharringtonine exerts strong cytotoxicity towards diffuse large B-cell lymphoma (DLBCL) cells and synergizes with BCL2 targeting agent ABT199 in eliminating BCL2-positive DLBCL cells. Blood. 2014;124(21):3645\u20135.","DOI":"10.1182\/blood.V124.21.3645.3645"},{"key":"224_CR81","unstructured":"Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood. 2013;122(21):872\u20132."},{"issue":"6","key":"224_CR82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3324\/haematol.2013.096107","volume":"99","author":"P Ghia","year":"2014","unstructured":"Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99(6):965\u201372.","journal-title":"Haematologica"},{"issue":"15_suppl","key":"224_CR83","first-page":"7015","volume":"32","author":"JF Seymour","year":"2014","unstructured":"Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, et al. ABT-199 (GDC-0199) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete- response rate and durable disease control. ASCO Meeting Abstr. 2014;32(15_suppl):7015.","journal-title":"ASCO Meeting Abstr"},{"issue":"15_suppl","key":"224_CR84","first-page":"8522","volume":"32","author":"MS Davids","year":"2014","unstructured":"Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. ASCO Meeting Abstr. 2014;32(15_suppl):8522.","journal-title":"ASCO Meeting Abstr"},{"key":"224_CR85","doi-asserted-by":"crossref","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, McKeegan E, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood. 2014;124(21):118\u20138.","DOI":"10.1182\/blood.V124.21.118.118"},{"issue":"15_suppl","key":"224_CR86","first-page":"7013","volume":"32","author":"S Ma","year":"2014","unstructured":"Ma S, Seymour JF, Lanasa MC, Kipps TJ, Barrientos JC, Davids MS, et al. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. ASCO Meeting Abstr. 2014;32(15_suppl):7013.","journal-title":"ASCO Meeting Abstr"},{"key":"224_CR87","doi-asserted-by":"crossref","unstructured":"Roberts AW, Ma S, Brander DM, Kipps TJ, Barrientos JC, Davids MS, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed \/ refractory (R\/R) chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):325\u20135.","DOI":"10.1182\/blood.V124.21.325.325"},{"issue":"15_suppl","key":"224_CR88","first-page":"TPS7120","volume":"32","author":"M Mobasher","year":"2014","unstructured":"Mobasher M, Huang J, Elstrom RL, Elhamy M, Bernaards C, Hallek MJ, et al. Multicenter, phase III, open-label, randomized study in relapsed\/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab. ASCO Meeting Abstr. 2014;32(15_suppl):TPS7120.","journal-title":"ASCO Meeting Abstr"},{"issue":"21","key":"224_CR89","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.V124.21.1722.1722","volume":"124","author":"S Vos de","year":"2014","unstructured":"de Vos S, Flowers CR, Wang D, Swinnen LJ, Fowler N, Reid E, et al. The BCL-2 inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. Blood. 2014;124(21):1722.","journal-title":"Blood"},{"issue":"21","key":"224_CR90","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/blood.V124.21.3337.3337","volume":"124","author":"GA Salles","year":"2014","unstructured":"Salles GA, Boyd TE, Morschhauser F, Wendtner C-M, Lymp J, Hilger J, et al. Preliminary results of a phase 1b study (GO28440) combining GDC-0199 (ABT-199) with bendamustine\/rituximab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2014;124(21):3337.","journal-title":"Blood"},{"issue":"21","key":"224_CR91","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood.V124.21.4687.4687","volume":"124","author":"I Flinn","year":"2014","unstructured":"Flinn I, Brunvand M, Dyer MJ, Hillman P, Jones J, Lymp J, et al. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2014;124(21):4687.","journal-title":"Blood"},{"issue":"15_suppl","key":"224_CR92","first-page":"TPS7121","volume":"32","author":"WG Wierda","year":"2014","unstructured":"Wierda WG, Seymour JF, Roberts AW, Puvvada S, Davids MS, Wong S, et al. A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion. ASCO Meeting Abstr. 2014;32(15_suppl):TPS7121.","journal-title":"ASCO Meeting Abstr"},{"issue":"26","key":"224_CR93","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","volume":"123","author":"V Fresquet","year":"2014","unstructured":"Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123(26):4111\u20139.","journal-title":"Blood"},{"key":"224_CR94","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"issue":"8","key":"224_CR95","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302\u20136.","journal-title":"Haematologica"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0224-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T12:50:26Z","timestamp":1599828626000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/8\/1\/129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0224-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]},"article-number":"129"}}